89bio — Technical Presentation (June 2022)
44 slides from 89bio's technical presentation, Jun 28, 2022
Slide 1: Pegozafermin Phase 2 (ENTRIGUE) Topline Results in SHTG
Nasdaq: ETNB Powerful Science Meaningful Medicines Changing Lives Pegozafermin Phase 2 (ENTRIGUE) Topline Results in Severe Hypertriglyceridemia (SHTG) Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of his
Slide 3: Results support advancing to Phase 3 – potential first FGF21 analog to market
Results support advancing to Phase 3 – potential first FGF21 analog to market Potentially quicker and efficient regulatory path to approval in SHTG Phase 3 initiation expected in 1H23; topline results ~ 2 years from study start ENTRIGUE results demonstrate compelling and differentiated profile in SH
Slide 4: SHTG is a Serious Disease in Need of Better Treatment Options
Average patient in ENTRIGUE study was estimated to have a 23% risk of Major Cardiovascular Events (MACE) over 10 years (per ACC ASCVD risk estimator) Average patient: no prior CV event, 54 years old, male, white, BP 131/81, total cholesterol 240, HDL 28, LDL 89, diabetic, non-smoker, taking anti-hyp
Slide 5: SHTG is a Large Underserved Market
High Prevalence Disease: ~4M patients in the United States SHTG is a Large Underserved Market Existing therapies have limitations Fish Oils: Minimal to moderate TG reduction, LDL elevations (some), no liver benefits Fibrates: Moderate TG reduction, major increase in LDL, myopathies Statins (not appr
Slide 6: Proposed Mechanisms of Action for Pegozafermin in SHTG
Stojsavljevic-Shapeski S et al J Clin Transl Hepatol 2021;9(1):51-59 Proposed Mechanisms of Action for Pegozafermin in SHTG Adipose tissue Decrease lipogenesis and release of FFA Improve insulin resistance Increase TG uptake Increase adiponectin Liver Increase β-oxidation Decrease de novo lipogenesi
Slide 7: ENTRIGUE Data
ENTRIGUE Data
Slide 8: ENTRIGUE – Phase 2 SHTG Trial Design
ENTRIGUE – Phase 2 SHTG Trial Design 8 Weeks SCREENING RANDOMIZATION SAFETY FOLLOW-UP 36mg Q2W Pegozafermin (n=16) 27mg QW Pegozafermin (n=18) 18mg QW Pegozafermin (n=17) 9mg QW Pegozafermin (n=16) PLACEBO (n=18) Safety analysis set, n=85 (patients who received at least 1 dose) Full analysis set, n=
Slide 9: Baseline Characteristics Represents an Advanced Population at High Risk for CV Disease
Baseline Characteristics Represents an Advanced Population at High Risk for CV Disease Parameter Mean or % Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=16) PGZ 18mg QW (n=17) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Total (n=85) Age (years) 57.5 52.7 54.6 49.2 53.9 53.1 53.7 Male (%) 66.7 77.6 68.8
Slide 10: Baseline Characteristics: Approximately 50% on Background Therapy
Baseline Characteristics: Approximately 50% on Background Therapy Represents Real World Setting Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=16) PGZ 18mg QW (n=17) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Total (n=85) Any background therapy 61% 54% 50% 53% 61% 50% 55% Statins/statin combo 50% 43% 38
Slide 11: Pegozafermin Significantly Reduces Triglycerides across All Dose Groups
Pegozafermin Significantly Reduces Triglycerides across All Dose Groups Primary Endpoint Median Percent Change in Triglycerides from Baseline at Week 8 Q2W QW p value vs placebo for change from baseline based on Wilcoxon Rank-Sum Test Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placeb
Slide 12: Significant Decrease in Triglycerides on Top of Background Therapy
Q2W QW Q2W QW Median Percent Change in Triglycerides from Baseline at Week 8 Pegozafermin Shows Significant Decrease in Triglycerides on Top of Background Therapy Not On Background Therapy On Background Therapy Full Analysis Set n=6 n=8 n=8 n=6 n=8 n=11 n=8 n=9 n=10 n=8 Background therapy defined as
Slide 13: Consistent Triglyceride Reduction across All Key Subgroups
Pegozafermin Shows Consistent and Significant Benefit in Triglyceride Reduction across All Key Subgroups Similar trends were observed in subgroup analyses based on other baseline characteristics N=(placebo, PGZ pooled) Placebo PGZ pooled Baseline TG ≥750 mg/dL Yes (n=4,23) -20% -63% No (n=13,42) 0%
Slide 14: Significant Decrease in Triglycerides at Different Threshold Levels
Full Analysis Set Pegozafermin Shows Significant Decrease in Triglycerides at Different Threshold Levels B. TG Normalization (<150mg/dL, <200mg/dL) Analysis via unstratified Chi-square test comparing the individual PGZ groups vs placebo. * p<0.05; ** p<0.01; *** p<0.001 versus placebo TG Responders
Slide 15: Clinically Meaningful Improvements in Non-HDL-C
p value vs placebo based on MMRM analysis; Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Pegozafermin Demonstrated Clinically Meaningful Improvements in Non-HDL-C – Key Marker of CV Risk Q2W QW Mean Percent Change from Baseline at Week 8 Non-HDL-C 218 Baseline (mg/dL): 216 203 2
Slide 16: Reduction in Absolute Non-HDL-C
Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo based on MMRM analysis Pegozafermin Demonstrated Reduction in Absolute Non-HDL-C Absolute Non-HDL-C Reduction is Associated with MACE Improvement Q2W QW Non-HDL-C Mean Absolute Change from Baseline at Week 8 218 Baseline (mg/dL): 216
Slide 17: Clinically Meaningful Improvements in Apo-B
QW Mean Percent Change from Baseline at Week 8 Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Pegozafermin Demonstrated Clinically Meaningful Improvements in Apo-B – Key Marker of CV Risk Apo-B Apo-B Q2W QW Q2W p value vs placebo based on MMRM analysis Mean Absolute Change from B
Slide 18: Significant Reduction in Liver Fat
Q2W QW Mean Relative Reduction in Liver Fat vs Baseline at Week 8 Pegozafermin Demonstrated Significant Reduction in Liver Fat Liver Fat Is an Important Potentiator of CV Risk MRI Analysis Set; p value vs placebo based on ANCOVA analysis *p <0.05 versus placebo n=6 n=3 n=5 n=7 n=2 Post-hoc analysis
Slide 19: Pegozafermin Improved Liver Function Despite Normal Levels at Baseline
Mean Percent Change from Baseline at Week 8 Full Analysis Set Pegozafermin Improved Liver Function Despite Normal Levels at Baseline ALT AST Q2W QW Q2W QW Baseline Mean ALT: 33 U/L (n=85) Baseline Mean AST: 25 U/L (n=85)
Slide 20: Improvement on HbA1c that May Increase with Longer Treatment
Pegozafermin Demonstrated Improvement on HbA1c that May Increase with Longer Treatment Full analysis set; MMRM analysis Absolute Change in HbA1c at Week 8 in ENTRIGUE Pooled Pooled Placebo Placebo Absolute change in HbA1c in 20-week NASH study Study BIO89-100-002; Cohort 7: n=10 at PGZ 27 mg QW HbA1
Slide 21: Pegozafermin Was Well Tolerated Across Doses
Pegozafermin Was Well Tolerated Across Doses Safety profile consistent with prior studies Preferred Term Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=12) PGZ 18mg QW (n=21) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Nausea 0 10% 0% 5% 22% 13% Diarrhea 0 9% 17% 5% 17% 13% Injection site reaction 0 9% 8
Slide 22: Pegozafermin – Unique and Differentiated Profile in SHTG
Pegozafermin – Unique and Differentiated Profile in SHTG Efficacy Significant reduction in triglycerides across all dose groups – up to 63% (27 mg QW) Results consistent in patients with or without background therapy Result consistent across various subgroups (high/low baseline TGs, Type 2 diabetes
Slide 23: Proposed Clinical Development
Proposed Clinical Development Regulatory Seek full approval using endpoint of triglyceride lowering (based on FDA precedent) Propose study duration and study size based on prior precedents for approved drugs Discuss safety database requirements for approval End of Phase 2 meeting planned for 2H22 Cl
Slide 24: Proposed Phase 3 SHTG Trial Design
Proposed Phase 3 SHTG Trial Design SCREENING RANDOMIZATION PLACEBO Pegozafermin^ Pegozafermin MAIN STUDY (12 weeks) EXTENSION PHASE* (12 weeks) PLACEBO Wk 12 Wk 24 PRIMARY ENDPOINT * Extension phase duration expected to be between 12 and 36 weeks TG ≥500 mg/dL Background therapy of statins and/or pr
Slide 25: Deepak L. Bhatt, MD, MPH
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Dr. Deepak L. Bhatt is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Health and Professor of Medicine at Harvard Medical School.
Slide 26: SHTG Represents a Significant Opportunity for Pegozafermin
SHTG Represents a Significant Opportunity for Pegozafermin
Slide 27: SHTG Represents a Large Population with High Unmet Needs
SHTG Represents a Large Population with High Unmet Needs Co-morbidity Prevalence in SHTG population Fatty Liver Disease (NAFLD) Up to 100% Type 2 diabetes/Prediabetes Up to 70% Dyslipidemia Up to 65% 850k 850k CONTROLLED UNCONTROLLED Prevalence Up to 4 million drug treated ~1.7 MILLION UN-treated ~1
Slide 28: Pegozafermin has Differentiated Profile Compared with Other TG-Lowering Drugs
In Development Approved Pegozafermin Potential APOC3 Fibrates Prescription Fish Oils Statins Pegozafermin Potential APOC3 Fibrates Vascepa Lovaza Statins Triglyceride reduction ✔✔✔ ✔✔✔ ✔✔ ✔ ✔✔ ✔✔ Liver fat reduction ✔ Worsens liver fat Insulin sensitizing ✔ Cholesterol lowering ✔ (non-HDL-C) ✔ (non-
Slide 29: Pegozafermin Profile Represents Substantial Potential in SHTG
Product profile testing Profile tested: 30% TG reduction plus 1 metabolic benefit (lower than ENTRIGUE data); audience: 150 physicians in 2020 Pegozafermin Profile Represents Substantial Potential in SHTG (Quantitative Market Research Results) Market Share* All Patients PatientS wITH fatty liver 1st
Slide 30: Corporate Highlights
Corporate Highlights Impacts a broad spectrum of cardio and metabolic endpoints Robust data in 2 indications with a favorable safety and tolerability profile Potential first-to-market FGF21 analog Pegozafermin – potential important new cardio-metabolic drug; balanced effect on multiple key endpoints
Slide 31: Plan To Advance Pegozafermin in Clinical Development
Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones SHTG End of Ph. 2 Meeting – 2H22 Phase 3 trial Initiation – 1H23 NASH Complete Enrollment – 3Q22 Topline Data – 1Q23 Plan To Advance Pegozafermin in Clinical Development Phase 2b trial Phase 3 trial - Planning
Slide 32: Appendix
Appendix
Slide 33: Pegozafermin Is an FGF21 Analog Optimally Engineered
Pegozafermin Is an FGF21 Analog Optimally Engineered to Balance Efficacy and Long Dosing Interval glycoPEG(20kD) C-terminus X Strong and flexible linker (glycoPEGylation technology) Mutations in positions 173 and 176 (glycoPEG attached at position 173) X N-terminus Position 182 FGF21 Proprietary gly
Slide 34: Pegozafermin Significantly Reduces Triglycerides across All Dose Groups
Pegozafermin Significantly Reduces Triglycerides across All Dose Groups Median Change in Absolute Triglyceride Levels from Baseline at Week 8 Q2W QW Full Analysis Set
Slide 35: Decrease in Triglycerides Regardless of Baseline TG Level
Median Percent Change in Triglycerides from Baseline at Week 8 Pegozafermin Demonstrated Significant Decrease in Triglycerides Regardless of Baseline TG Level Category Baseline TG ≥750 mg/dL Q2W QW Baseline TG <750 mg/dL Q2W QW Full Analysis Set. n=11 n=12 n=10 n=9 n=4 n=5 n=5 n=6 n=7 n=13
Slide 36: Decrease in Triglycerides Regardless of Diabetes Status
Median Percent Change in Triglycerides from Baseline at Week 8 Pegozafermin Demonstrated Significant Decrease in Triglycerides Regardless of Diabetes Status Patients with T2DM Patients without T2DM Q2W QW Q2W QW Full Analysis Set n=10 n=9 n=6 n=9 n=7 n=7 n=7 n=11 n=7 n=9
Slide 37: Clinically Meaningful Improvements in HDL-C
Mean Percent Change from Baseline at Week 8 Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Pegozafermin Demonstrated Clinically Meaningful Improvements in HDL-C HDL-C Q2W QW Q2W QW p value vs placebo based on MMRM analysis Mean Absolute Change from Baseline at Week 8 HDL-C 29 Bas
Slide 38: Decrease in Triglycerides on Top of Statins, Fish Oils and Fibrates
Pegozafermin Shows Significant Decrease in Triglycerides on Top of Statins, Prescription Fish Oils and Fibrates Full Analysis Set Background therapy defined as concomitant lipid-modifying therapy Median Percent Change in Triglycerides from Baseline at Week 8 Placebo n=9 PGZ pooled n=28 Placebo n=3 P
Slide 39: Improvements in HDL-C and No Change in LDL-C vs. Placebo
Mean Percent Change from Baseline at Week 8 Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 versus placebo Pegozafermin Demonstrated Clinically Meaningful Improvements in HDL-C and No Change in LDL-C vs. Placebo HDL-C p value vs placebo based on MMRM analysis Mean Percent Change from Baseline at
Slide 40: Consistent and Robust Effects in Two Indications (SHTG and NASH)
Pegozafermin 27mg QW Showed Consistent and Robust Effects in Two Indications (SHTG Patients at 8 weeks and NASH Patients at 20 weeks) ` LIVER HEALTH DYSLIPIDEMA INSULIN RESISTANCE ^Mean change from baseline; TG data for SHTG is presented as median SHTG results represents data at 8 weeks from BIO89-1
Slide 41: Target Product Profile Criteria for a New Therapy
Target Product Profile Criteria for a New Therapy (Physician and KOL Research Completed by 89bio Before ENTRIGUE Data Readout) Triglyceride efficacy 30% as add-on therapy (50% is upside case) 30% achieve TG <500 mg (50% is upside case) Cardiometabolic benefits offer added value Liver Fat reduction:
Slide 42: KOL Experts & Physicians – Pegozafermin profile is unique and compelling
KOL Experts & Physicians – Pegozafermin profile is unique and compelling Target patient Patient with uncontrolled TGs despite drug therapy or past episode of acute pancreatitis Patient with history of cardiovascular risk factors Patients with background metabolic syndrome symptoms Ideal profile – re
Slide 43: Payers – Managed Care Directors and PBMs
Payers – Managed Care Directors and PBMs Pegozafermin has potential to gain broad coverage based on approved indication; market is not actively managed Data supportive of premium pricing in 2nd line setting (threshold – 30% reduction in TG) We believe that majority of plans would place pegozafermin
Slide 44: Current Therapies Have Had Commercial Success Despite Less than Ideal Profiles
SAFETY / TOLERABILITY FISH OILS FIBRATES Vascepa (EPA) Lovaza (EPA+DHA) Tricor May prolong bleeding time Myopathy, Creatinine increases, DDI Current Therapies Have Had Commercial Success Despite Less than Ideal Profiles TG LDL-C Changes from baseline Vascepa Lovaza Tricor ~$1B (Peak) >~$1B (Peak) ~$